Trastuzumab emtansine (Kadcyla)
General information
Class: Antibody (trastuzumab) with linker to chemotherapeutic agent (emtansine). Humanized monoclonal antibody binds to subdomain IV of HER2, facilitating targeted delivery of a maytansine derivative that binds to tubulin at the rhizoxin binding site and inhibits the assembly of microtubules.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert.
Patient drug information
No information available.
References
- ↑ ImmunoGen product site
- ↑ http://www.immunogen.com/img/T-DM1%20+%20pertuzumab%20at%20SABCS.pdf A Phase Ib/II Trial of Trastuzumab-DM1 (T-DM1) with Pertuzumab for Patients with HER2-Positive, Locally Advanced or Metastatic Breast Cancer: Interim Efficacy and Safety Results
- ↑ Dr. Sara Hurvitz's 2011 European Society for Medical Oncology (ESMO) Presentation